Renal Hypertension disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: RNL015 MIFTS: 47	Renal Hypertension Categories: Cardiovascular diseases, Ear diseases, Genetic diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Renal Hypertension

MalaCards integrated aliases for Renal Hypertension:

Name: Renal Hypertension ¹² ⁷⁴ ¹⁵ ¹⁷ ⁷¹

Hypertension, Renal ⁴³

Hypertension Renal ⁵⁴

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Cardiovascular diseases Nephrological diseases Ear diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1073

MeSH ⁴³ D006977

NCIt ⁴⁹ C3121

SNOMED-CT ⁶⁷ 28119000

EFO ¹⁷ EFO_1002039

UMLS ⁷¹ C0020544

Sources

Summaries for Renal Hypertension

MalaCards based summary : Renal Hypertension, also known as hypertension, renal, is related to chronic pyelonephritis and hypertensive nephropathy. An important gene associated with Renal Hypertension is EDN1 (Endothelin 1), and among its related pathways/superpathways are Pathways in cancer and Development Angiotensin activation of ERK. The drugs Hydrochlorothiazide and Indapamide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : ⁷⁴ Renovascular hypertension is a condition in which high blood pressure is caused by the kidneys' hormonal... more...

Sources

Related Diseases for Renal Hypertension

Diseases in the Renal Hypertension family:

Renal Failure, Progressive, with Hypertension

Diseases related to Renal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)

#	Related Disease	Score	Top Affiliating Genes
1	chronic pyelonephritis	30.8	REN ALB ACE
2	hypertensive nephropathy	30.8	ALB AGTR1 ACE
3	familial hypertension	30.6	REN AGTR1 AGT
4	uremia	30.5	REN EPO ALB ACE
5	hypertension, diastolic	30.5	REN ACE
6	acute kidney failure	30.5	REN KNG1 ALB
7	pure autonomic failure	30.4	REN EPO DBH ACE
8	fibromuscular dysplasia	30.4	REN AGTR1 AGT ACE
9	renovascular hypertension	30.4	REN NPPB NOS3 KNG1 EDN1 AGTR1
10	renal fibrosis	30.4	REN MIR200B ALB AGTR1 AGT
11	glomerulonephritis	30.3	MYH9 APOL1 ALB AGTR1 ACE
12	cystic kidney disease	30.3	REN EPO ALB ACE
13	atherosclerosis susceptibility	30.3	NOS3 EDN1 ALB AGTR1 ACE
14	hepatorenal syndrome	30.3	REN EDN1 ALB ACE
15	hypertensive retinopathy	30.2	REN ALB AGTR1 ACE
16	malignant hypertension	30.2	REN NPPB EDN1 AGTR1 AGT ADM
17	microvascular complications of diabetes 3	30.2	REN ALB AGTR1 ACE
18	kidney hypertrophy	30.2	REN ALB ACE
19	malignant renovascular hypertension	30.1	REN EDN1 AGTR1
20	coronary stenosis	30.1	NPPB ALB ACE
21	portal hypertension	30.1	NOS3 EDN1 ALB AGTR1 ACE
22	liver cirrhosis	30.0	REN KLKB1 EDN1 ALB ADM
23	hypokalemia	30.0	SLC12A3 REN ALB ACE
24	gitelman syndrome	30.0	SLC12A3 REN AGT
25	pheochromocytoma	30.0	REN KNG1 EPO EDN1 DBH ADM
26	urinary tract obstruction	29.9	REN ALB AGTR1 ACE
27	liddle syndrome 1	29.9	SLC12A3 REN AGT
28	hypertensive encephalopathy	29.9	REN NOS3 EPO ALB AGTR1 ACE
29	renal tubular dysgenesis	29.8	REN AGTR1 AGT ACE
30	renal dysplasia	29.8	REN AGTR1 AGT ACE
31	retinal vascular disease	29.8	REN NOS3 EDN1 ALB ACE
32	peripheral vascular disease	29.7	NOS3 KNG1 EPO ALB ACE
33	focal segmental glomerulosclerosis	29.7	MYH9 APOL1 ALB AGTR1 ACE
34	coronary heart disease 1	29.7	NPPB NOS3 EDN1 AGTR1 ACE
35	hypertensive heart disease	29.7	REN NPPB AGTR1 AGT ACE
36	ischemia	29.5	NPPB NOS3 KNG1 EPO EDN1 ACE
37	pulmonary hypertension	29.5	REN NPPB NOS3 EDN1 ALB AGTR1
38	sleep apnea	29.5	REN NPPB NOS3 EPO EDN1 ALB
39	eclampsia	29.5	REN NOS3 EDN1 ALB AGT ACE
40	polycystic kidney disease	29.4	REN NOS3 EPO EDN1 ALB AGTR1
41	diastolic heart failure	29.4	REN NPPB NOS3 AGTR1 AGT ACE
42	vascular disease	29.4	REN NPPB NOS3 KNG1 EPO EDN1
43	pre-eclampsia	29.3	REN NOS3 KNG1 EDN1 ALB AGTR1
44	autosomal dominant polycystic kidney disease	29.2	REN NOS3 EDN1 ALB AGTR1 AGT
45	body mass index quantitative trait locus 11	29.2	REN NOS3 KNG1 EDN1 ALB AGT
46	pulmonary edema	29.1	REN NPPB NOS3 KNG1 EPO EDN1
47	diabetes mellitus	29.0	REN NPPB NOS3 KNG1 EPO EDN1
48	end stage renal disease	29.0	REN NOS3 MYH9 EPO APOL1 ALB
49	chronic kidney disease	28.8	REN NPPB NOS3 MYH9 EPO EDN1
50	kidney disease	28.6	SLC12A3 REN NPPB NOS3 MYH9 MIR200A

Graphical network of the top 20 diseases related to Renal Hypertension:

Sources

Symptoms & Phenotypes for Renal Hypertension

MGI Mouse Phenotypes related to Renal Hypertension:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.97	ACE ADM AGT AGTR1 ALB DBH
2	homeostasis/metabolism	MP:0005376	9.8	ACE ADM AGT AGTR1 ALB DBH
3	renal/urinary system	MP:0005367	9.32	ACE ADM AGT AGTR1 ALB EDN1

Sources

Drugs & Therapeutics for Renal Hypertension

Drugs for Renal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Indapamide

Approved

Phase 4

26807-65-8

3702

Angiotensin II

Approved, Investigational

Phase 4

4474-91-3, 11128-99-7, 68521-88-0

172198

Candesartan cilexetil

Approved

Phase 4

145040-37-5

2540

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Captopril

Approved

Phase 4

62571-86-2

44093

Amlodipine

Approved

Phase 4

88150-42-9

2162

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Candesartan

Experimental

Phase 4

139481-59-7

2541

Sodium Chloride Symporter Inhibitors

Phase 4

Angiotensin-Converting Enzyme Inhibitors

Phase 4

Angiotensin Receptor Antagonists

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Angiotensinogen

Phase 4

Giapreza

Phase 4

HIV Protease Inhibitors

Phase 4

protease inhibitors

Phase 4

Adrenergic beta-1 Receptor Antagonists

Phase 4

Adrenergic Agents

Phase 4

Hormones

Phase 4

Adrenergic Antagonists

Phase 4

Vasodilator Agents

Phase 4

Sympatholytics

Phase 4

Adrenergic beta-Antagonists

Phase 4

Neurotransmitter Agents

Phase 4

Calcium, Dietary

Phase 4

calcium channel blockers

Phase 4

Antihypertensive Agents

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Telmisartan

Approved, Investigational

Phase 3

144701-48-4

65999

Losartan

Approved

Phase 3

114798-26-4

3961

Atenolol

Approved

Phase 3

29122-68-7

2249

Lisinopril

Approved, Investigational

Phase 3

76547-98-3, 83915-83-7

5362119

Diltiazem

Approved, Investigational

Phase 3

42399-41-7

39186

Hydralazine

Approved

Phase 3

86-54-4

3637

Metoprolol

Approved, Investigational

Phase 3

37350-58-6, 51384-51-1

4171

Minoxidil

Approved, Investigational

Phase 3

38304-91-5

4201

Clonidine

Approved

Phase 3

4205-90-7

2803

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

Magnesium citrate

Approved

Phase 3

3344-18-1

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

Dimenhydrinate

Approved

Phase 3

523-87-5

441281

Bisacodyl

Approved

Phase 3

603-50-9

Chlorothiazide

Approved, Vet_approved

Phase 3

58-94-6

2720

Spironolactone

Approved

Phase 3

52-01-7, 1952-01-7

5833

Mycophenolic acid

Approved

Phase 3

24280-93-1

446541

Tacrolimus

Approved, Investigational

Phase 3

104987-11-3

445643 439492 6473866

tannic acid

Approved

Phase 3

1401-55-4

Benzocaine

Approved, Investigational

Phase 3

94-09-7, 1994-09-7

2337

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Interventional clinical trials:

(show top 50) (show all 143)

#	Name	Status	NCT ID	Phase	Drugs
1	Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension	Completed	NCT01656096	Phase 4
2	A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension	Completed	NCT01172431	Phase 4	Indapamide;Hydrochlorothiazide
3	Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial.	Completed	NCT01734096	Phase 4	Candesartan cilexetil
4	An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus	Completed	NCT00660309	Phase 4	Aliskiren;Irbesartan;Captopril
5	Renal Denervation in Patients With Resistant Hypertension	Completed	NCT01570777	Phase 4
6	Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.	Active, not recruiting	NCT04085562	Phase 4	Bisoprolol Fumarate 5-10 mg;Amlodipine 5-10 mg
7	Renal Denervation for Complicated Hypertension (RDNP-2012-03)	Terminated	NCT01865253	Phase 4
8	Renal Denervation for Resistant Hypertension	Terminated	NCT01865240	Phase 4
9	DENERVATION OF RENAL SYMPATHETIC ACTIVITY AND HYPERTENSION STUDY	Unknown status	NCT01522430	Phase 3
10	Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction	Unknown status	NCT01583881	Phase 2, Phase 3
11	Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection	Unknown status	NCT00868972	Phase 2, Phase 3
12	A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction	Completed	NCT01593787	Phase 3	LCZ696
13	Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial	Completed	NCT01850901	Phase 3
14	Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome	Completed	NCT00723801	Phase 3	Atenolol;Losartan
15	HALT Progression of Polycystic Kidney Disease Study B	Completed	NCT01885559	Phase 3	Lisinopril;Telmisartan;Placebo
16	HALT Progression of Polycystic Kidney Disease Study A	Completed	NCT00283686	Phase 3	Lisinopril;Telmisartan;Placebo
17	Treatment of Masked Hypertension	Completed	NCT02142881	Phase 3
18	A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy	Completed	NCT01778192	Phase 3	Polyethylene glycol;Polyethylene glycol;Sodium picosulphate with magnesium citrate;Sodium picosulphate with magnesium citrate
19	Bevacizumab Pretreatment and Long Acting Gas Infusion on the Vitreous Clear-up After Diabetic Vitrectomy	Completed	NCT00656435	Phase 3	Bevacizumab
20	Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation	Completed	NCT03074448	Phase 3	Sodium Picosulfate
21	Treatment of Hypertension	Completed	NCT00000484	Phase 3	chlorothiazide;Rauwolfia alkaloids
22	A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects With Hypertension	Recruiting	NCT02910414	Phase 3	Dehydrated alcohol
23	Renal Denervation Using the OneShot Ablation System	Terminated	NCT01844037	Phase 2, Phase 3
24	Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial	Terminated	NCT01762488	Phase 3
25	Renal Denervation - Hope for Patients With Refractory Hypertension?	Terminated	NCT01560312	Phase 3
26	Evaluation of the Benefit/Risk Ratio of a Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil on the Prevention of Complications in Adult Liver Transplantation	Terminated	NCT00151632	Phase 3	Mycophenolate mofetil;Tacrolimus
27	Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II	Withdrawn	NCT01939392	Phase 2, Phase 3
28	High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure	Unknown status	NCT02608632	Phase 2
29	Renal Denervation in Patients With Uncontrolled Hypertension in Chinese	Unknown status	NCT01390831	Phase 1, Phase 2
30	Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study)	Unknown status	NCT02002585	Phase 2
31	Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery	Unknown status	NCT02314286	Phase 1, Phase 2	Rosuvastatin;Placebo
32	The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant	Completed	NCT00446459	Phase 2	mycophenolate mofetil (CellCept)
33	The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.	Completed	NCT00446251	Phase 2	Rituximab;Mycophenolate mofetil (MMF)
34	A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications	Recruiting	NCT03503773	Phase 2	Alcohol
35	Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF)	Recruiting	NCT02432339	Phase 1, Phase 2	mycophenolate mofetil (MMF);Placebo
36	Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography	Active, not recruiting	NCT01673516	Phase 2
37	A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure	Terminated	NCT03152552	Phase 2	LIK066;Placebo;Empagliflozin
38	Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension	Terminated	NCT02653222	Phase 2
39	A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157)	Completed	NCT02095691	Phase 1
40	A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02)	Completed	NCT01756300	Phase 1
41	Renal Denervation in Patients With Refractory Hypertension	Completed	NCT00483808	Phase 1
42	Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients	Completed	NCT01491919	Phase 1	Lisinopril
43	Phase 1 Study of Oral L-citrulline on ADMA/L-arginine and Endothelial-dependent Vascular Function in Pregnancy.	Completed	NCT00743210	Phase 1	L-citrulline;Placebo
44	Nurse's Role in the Management of Hyperprolactinemia: A Prospective Randomized Controlled Trial	Recruiting	NCT04262024	Phase 1	Cabergoline 0.5Mg orally daily for 1 month plus health education by a nurse;Cabergoline 0.5Mg orally daily for 1 month without health education by a nurse
45	Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation	Unknown status	NCT02164435
46	Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)	Unknown status	NCT01785732
47	Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension	Unknown status	NCT02029885
48	Wave VI Feasibility Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension	Unknown status	NCT02480517
49	A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension	Unknown status	NCT02690909
50	Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter	Unknown status	NCT02115230

Search NIH Clinical Center for Renal Hypertension

Cochrane evidence based reviews: hypertension, renal

Sources

Genetic Tests for Renal Hypertension

Sources

Anatomical Context for Renal Hypertension

MalaCards organs/tissues related to Renal Hypertension:

⁴⁰

Kidney, Heart, Testes, Liver, Endothelial, Brain, Skin

Sources

Publications for Renal Hypertension

Articles related to Renal Hypertension:

(show top 50) (show all 3200)

#	Title	Authors	PMID	Year
1	[Management of renal atrophy in hypertensive patients: experience in Lille]. ⁵⁴ ⁶¹	Marboeuf P...Mounier-Vehier C	19854024	2010
2	Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. ⁶¹ ⁵⁴	Modesti PA...Parati G	16982943	2006
3	Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. ⁶¹ ⁵⁴	Masoudi FA...Krumholz HM	16168275	2005
4	Association study of calcitonin-receptor-like receptor gene in essential hypertension. ⁶¹ ⁵⁴	Sano M...Kokubun S	15797661	2005
5	The clinical use of angiotensin-converting enzyme inhibitors. ⁶¹ ⁵⁴	Wong J...Kowey PR	15586352	2004
6	Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? ⁵⁴ ⁶¹	Doggrell SA	12437489	2002
7	Methods for assessing endothelin ETA-receptor antagonists in preclinical studies. ⁵⁴ ⁶¹	Okada M...Nishikibe M	12224443	2002
8	Endothelin and heart failure. ⁵⁴ ⁶¹	Nambi P...Feuerstein G	11447308	2001
9	Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade. ⁶¹ ⁵⁴	Basile JN	11675775	2001
10	Development of ideas on renovascular hypertension. ⁶¹ ⁵⁴	Peart S	11022890	2000
11	[The protection of renal function in the ACEI treatment of renal hypertension]. ⁶¹ ⁵⁴	Zhou QL...Chen LP	12206011	2000
12	Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor. ⁵⁴ ⁶¹	Abe F...Takanashi N	10604545	1999
13	[Adrenomedullin]. ⁵⁴ ⁶¹	Beltowski J	10352550	1999
14	[Study on the relationship between plasma endothelin nitric oxide concentration and renal hypertension and renal function]. ⁵⁴ ⁶¹	Zhou Q...Zhou H	12080656	1999
15	Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. ⁵⁴ ⁶¹	Yusuf S...Lonn E	9796839	1998
16	Endothelin as a regulator of cardiovascular function in health and disease. ⁵⁴ ⁶¹	Haynes WG...Webb DJ	9794709	1998
17	Adrenomedullin: a new modulator of vascular tone. ⁵⁴ ⁶¹	Kangawa K...Matsuo H	8951571	1996
18	Adrenomedullin: a new hypotensive peptide. ⁵⁴ ⁶¹	Kangawa K...Matsuo H	9120666	1996
19	[Arterial hypertension in patients on chronic hemodialysis]. ⁶¹ ⁵⁴	Zogovic J...Mladenovic Lj	9102857	1996
20	Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. ⁵⁴ ⁶¹	Omata K...Abe K	8743512	1996
21	[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]. ⁶¹ ⁵⁴	Spustova V...Dzurik R	8686202	1996
22	Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. ⁶¹ ⁵⁴	Zhu YC...Unger T	8846416	1995
23	Relation between renin and prorenin in plasma from hypertensive patients and normal people: evidence for different renin:prorenin ratios. ⁶¹ ⁵⁴	Leckie BJ...Morton JJ	7473533	1995
24	[The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases]. ⁵⁴ ⁶¹	Kutyrina IM...Miroshnichenko NG	7638769	1995
25	Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. ⁶¹ ⁵⁴	O'Connor DT...Biaggioni I	8143425	1994
26	Renal vein renin analysis: limitations of its use in predicting benefit from percutaneous angioplasty. ⁶¹ ⁵⁴	Martin LG...Wells JO	8485747	1993
27	Urinary kallikrein excretion is low in malignant essential hypertension. ⁶¹ ⁵⁴	Hilme E...Hansson L	1325521	1992
28	Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. ⁵⁴ ⁶¹	Ajayi AA	1908620	1991
29	Antihypertensive effects of allicin on spontaneously hypertensive rats via vasorelaxation and hydrogen sulfide mechanisms. ⁶¹	Cui T...Zhang JY	32480217	2020
30	No news is good news? Three-year postdischarge mortality of octogenarian and nonagenarian patients following emergency general surgery. ⁶¹	Narueponjirakul N...Kaafarani HMA	32569106	2020
31	Rapidly progressive glomerulonephritis and acute kidney injury associated with cocaine use - Case report. ⁶¹	Pimentel PVS...Daher EF	32573647	2020
32	Cardiovascular Health in American Indians and Alaska Natives: A Scientific Statement From the American Heart Association. ⁶¹	Breathett K...American Heart Association Council on Epidemiology and Prevention; Council on Quality of Care and Outcomes Research; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health	32460555	2020
33	Disparity in access to bariatric surgery among African-American men. ⁶¹	Hoffman AB...Noyes K	31385077	2020
34	Renal sympathetic nerve activity regulates cardiovascular energy expenditure in rats fed high salt. ⁶¹	Morisawa N...Nishiyama A	31932643	2020
35	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. ⁶¹	Butler J...Braunwald E	31682908	2020
36	Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus. ⁶¹	Dent EL...Ryan MJ	32150445	2020
37	Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer. ⁶¹	Kong SH...Shin CS	32405760	2020
38	Intracranial vascular pathology in two further patients with Floating-Harbor syndrome: Proposals for cerebrovascular disease risk management. ⁶¹	Menzies L...Hurst JA	31605816	2020
39	Increased Mortality in Asians With Systemic Sclerosis in Northern California. ⁶¹	Chung MP...Chung L	32198914	2020
40	E/e' in relation to outcomes in ST-elevation myocardial infarction. ⁶¹	Tai SB...Sahlen A	32242982	2020
41	Correlations Between Interleukin-11 Expression and Hypertensive Kidney Injury in a Rat Model of Renovascular Hypertension. ⁶¹	Menendez-Castro C...Hilgers KF	31840157	2020
42	Fragmented QRS in prediction of ischemic heart disease diagnosed by stress cardiovascular magnetic resonance imaging. ⁶¹	Yooprasert P...Tangcharoen T	32320122	2020
43	α2A-Adrenoceptors Modulate Renal Sympathetic Neurotransmission and Protect against Hypertensive Kidney Disease. ⁶¹	Hering L...Stegbauer J	32086277	2020
44	Does race impact functional outcomes in patients undergoing robotic partial nephrectomy? ⁶¹	Falagario UG...Badani KK	32420201	2020
45	A Positive Cocaine Urine Toxicology Test and the Effect on Intraoperative Hemodynamics Under General Anesthesia. ⁶¹	Moon TS...Ogunnaike B	32304462	2020
46	Overall survival and factors predicting long-term outcome after thoracic aortic endovascular repair. ⁶¹	De Coster B...Maleux G	32126933	2020
47	No News is Good News? Three-year Post-Discharge Mortality of Octogenarian and Nonagenarian Patients Following Emergency General Surgery. ⁶¹	Narueponjirakul N...Kaafarani HMA	32251266	2020
48	Afferent innervation of the ischemic kidney contributes to renal dysfunction in renovascular hypertensive rats. ⁶¹	Lopes NR...Nishi EE	31925527	2020
49	Epidemiology, Comorbidities, and Outcomes of Posterior Reversible Encephalopathy Syndrome in Children in the United States. ⁶¹	Thavamani A...Ghori A	31481327	2020
50	Hypertensive Disorders of Pregnancy and Future Cardiovascular Health. ⁶¹	Melchiorre K...Khalil A	32351977	2020

Sources

Genes for Renal Hypertension

Genes related to Renal Hypertension (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	EDN1	Endothelin 1	Protein Coding	18.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12080656 16982943 11447308 (more) 9794709 12206011 12224443
2	REN	Renin	Protein Coding	17.66	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11022890 9102857 19854024 (more) 8485747 7473533
3	ACE	Angiotensin I Converting Enzyme	Protein Coding	15.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	15586352 8743512 16168275 (more) 7638769 11675775 12437489 1908620 9796839 10604545 8686202
4	ALB	Albumin	Protein Coding	12.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	EPO	Erythropoietin	Protein Coding	11.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KLKB1	Kallikrein B1	Protein Coding	10.91	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	1325521
7	ADM	Adrenomedullin	Protein Coding	10.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	9120666 10352550 8951571 (more) 15797661
8	KNG1	Kininogen 1	Protein Coding	10.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	8846416
9	SLC12A3	Solute Carrier Family 12 Member 3	Protein Coding	10.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	NPPB	Natriuretic Peptide B	Protein Coding	10.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	MIR200B	MicroRNA 200b	RNA Gene	8.81	DISEASES inferred ¹⁵ ¹⁵
12	MIR141	MicroRNA 141	RNA Gene	8.81	DISEASES inferred ¹⁵ ¹⁵
13	MIR200A	MicroRNA 200a	RNA Gene	8.74	DISEASES inferred ¹⁵ ¹⁵
14	AGTR1	Angiotensin II Receptor Type 1	Protein Coding	7.52	DISEASES inferred ¹⁵
15	DBH	Dopamine Beta-Hydroxylase	Protein Coding	7.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	8143425
16	GPR182	G Protein-Coupled Receptor 182	Protein Coding	6.78	Novoseek inferred ⁵⁴	9120666 8951571
17	APOL1	Apolipoprotein L1	Protein Coding	6.72	DISEASES inferred ¹⁵
18	NOS3	Nitric Oxide Synthase 3	Protein Coding	6.66	DISEASES inferred ¹⁵
19	AGT	Angiotensinogen	Protein Coding	6.63	DISEASES inferred ¹⁵
20	MYH9	Myosin Heavy Chain 9	Protein Coding	6.41	DISEASES inferred ¹⁵
21	ACE2	Angiotensin I Converting Enzyme 2	Protein Coding	6.32	DISEASES inferred ¹⁵
22	FN1	Fibronectin 1	Protein Coding	6.3	DISEASES inferred ¹⁵
23	KLK4	Kallikrein Related Peptidase 4	Protein Coding	6.28	DISEASES inferred ¹⁵
24	AGTR2	Angiotensin II Receptor Type 2	Protein Coding	6.17	DISEASES inferred ¹⁵
25	NPHS1	NPHS1 Adhesion Molecule, Nephrin	Protein Coding	6.15	DISEASES inferred ¹⁵
26	CYBB	Cytochrome B-245 Beta Chain	Protein Coding	6.14	DISEASES inferred ¹⁵
27	NOX4	NADPH Oxidase 4	Protein Coding	6.1	DISEASES inferred ¹⁵
28	ADRB1	Adrenoceptor Beta 1	Protein Coding	6.1	DISEASES inferred ¹⁵
29	CRP	C-Reactive Protein	Protein Coding	6.06	DISEASES inferred ¹⁵

Sources

Variations for Renal Hypertension

Sources

Expression for Renal Hypertension

Search GEO for disease gene expression data for Renal Hypertension.

Sources

Pathways for Renal Hypertension

Pathways related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁶	12.62	KNG1 EPO EDN1 AGTR1 AGT
2	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.59	NOS3 EPO EDN1 AGTR1 AGT
3	cGMP-PKG signaling pathway ³⁶ Show member pathways Adrenergic signaling in cardiomyocytes ³⁶	12.27	NPPB NOS3 KNG1 AGTR1 AGT
4	Oxytocin signaling pathway ³⁶ Show member pathways Vascular smooth muscle contraction ³⁶	11.96	NPPB NOS3 MYH9 EDN1 AGTR1 AGT
5	AGE-RAGE signaling pathway in diabetic complications ³⁶	11.62	NOS3 EDN1 AGTR1 AGT
6	HIF-1-alpha transcription factor network ¹	11.47	EPO EDN1 ADM
7	Renin secretion ³⁶	11.39	REN EDN1 AGTR1 AGT ACE
8	HIF1Alpha Pathway ⁶³	11.37	NOS3 EPO EDN1
9	miRNA targets in ECM and membrane receptors ¹	11.21	MIR200B MIR200A MIR141
10	Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE Inhibitor Pathway ¹ ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Renin-angiotensin system ³⁶	11	REN NOS3 KNG1 AGTR1 AGT ACE
11	Sympathetic Nerve Pathway (Neuroeffector Junction) ⁶⁰	10.79	GPR182 DBH ADM

Sources

GO Terms for Renal Hypertension

Cellular components related to Renal Hypertension according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell	GO:0005623	9.76	SLC12A3 NOS3 MYH9 KNG1 EDN1 AGTR1
2	extracellular region	GO:0005576	9.73	REN NPPB KNG1 KLKB1 EPO EDN1
3	blood microparticle	GO:0072562	9.56	KNG1 APOL1 ALB AGT
4	extracellular space	GO:0005615	9.44	REN NPPB MIR141 KNG1 KLKB1 EPO

Biological processes related to Renal Hypertension according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell proliferation	GO:0008284	10.02	MIR200B MIR141 EPO EDN1 AGT ADM
2	response to lipopolysaccharide	GO:0032496	9.85	REN NOS3 EPO EDN1 ADM
3	kidney development	GO:0001822	9.81	REN AGTR1 AGT ACE
4	positive regulation of cytosolic calcium ion concentration	GO:0007204	9.8	KNG1 EDN1 AGTR1 AGT ADM
5	vasodilation	GO:0042311	9.65	NOS3 KNG1 AGT
6	amyloid-beta metabolic process	GO:0050435	9.63	REN ACE
7	positive regulation of urine volume	GO:0035810	9.63	NPPB EDN1
8	low-density lipoprotein particle remodeling	GO:0034374	9.62	AGTR1 AGT
9	negative regulation of blood coagulation	GO:0030195	9.62	KNG1 EDN1
10	blood vessel remodeling	GO:0001974	9.62	NOS3 DBH AGT ACE
11	angiotensin maturation	GO:0002003	9.61	REN ACE
12	response to dexamethasone	GO:0071548	9.61	EPO EDN1
13	positive regulation of renal sodium excretion	GO:0035815	9.61	NPPB EDN1 AGT
14	artery smooth muscle contraction	GO:0014824	9.6	EDN1 AGT
15	positive regulation of cholesterol esterification	GO:0010873	9.59	AGTR1 AGT
16	body fluid secretion	GO:0007589	9.58	NPPB EDN1
17	positive regulation of NAD(P)H oxidase activity	GO:0033864	9.58	AGTR1 AGT
18	regulation of systemic arterial blood pressure by endothelin	GO:0003100	9.57	NOS3 EDN1
19	regulation of renal sodium excretion	GO:0035813	9.56	AGTR1 AGT
20	regulation of blood vessel diameter by renin-angiotensin	GO:0002034	9.54	AGTR1 AGT
21	regulation of systemic arterial blood pressure by renin-angiotensin	GO:0003081	9.54	AGTR1 AGT ACE
22	regulation of blood volume by renin-angiotensin	GO:0002016	9.52	REN AGT
23	regulation of renal output by angiotensin	GO:0002019	9.49	AGT ACE
24	regulation of vasoconstriction	GO:0019229	9.46	EDN1 AGTR1 AGT ACE
25	renin-angiotensin regulation of aldosterone production	GO:0002018	9.43	REN AGTR1 AGT
26	regulation of blood vessel diameter	GO:0097746	9.26	NPPB NOS3 AGTR1 ACE
27	regulation of blood pressure	GO:0008217	9.1	REN NPPB NOS3 EDN1 AGT ACE

Molecular functions related to Renal Hypertension according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	9.55	REN NPPB KNG1 EDN1 ADM
2	hormone activity	GO:0005179	9.02	NPPB EPO EDN1 AGT ADM
3	bradykinin receptor binding	GO:0031711	8.96	AGTR1 ACE

Sources

Sources for Renal Hypertension

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia